# Neuralink — Healthcare Investment Intelligence

> other · Series B. MedFuel Intel profile as of 2026-06-12.

Neuralink is a neurotechnology company developing implantable brain-computer interfaces (BCIs) for treating brain diseases and human enhancement. As of 2024, it has conducted human implants and clinical trials, with significant funding including a Series D round in 2023 valuing the company at $5 billion.[1][5]

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series B
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 25/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.